Korsana Biosciences 3Q 2026: EPS ($3.19) — 10-Q Summary
Menos de 1 minuto de leitura
Korsana reported a wider net loss in the third quarter as research and development and general and administrative expenses increased. Higher costs included additional stock-based compensation, spending on undisclosed programs, and personnel-related and chemistry, manufacturing and development costs; lower Aβ program payments to Paragon partly offset the increases.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Net income² | ($46.43M) | ($21.72M) | (113.7%) |
| Diluted EPS³ | ($3.19) | ($39.49) | 91.9% |
² Reported as “Net loss and comprehensive loss”. ³ Reported as “Net loss per share attributable to common stockholders, basic and diluted”.
Business Highlights
- KRSA-028: The company plans to submit a CTN in Australia or a CTA in New Zealand by the end of 2026 and an IND in the U.S. in the first quarter of 2027.
- Development outlook: Pharmacokinetic data in healthy volunteers is anticipated by mid-year 2027; interim proof-of-concept data in Alzheimer’s disease patients is anticipated by year-end 2027 or the first quarter of 2028.
- Research spending: Third-quarter R&D expenses rose to $42.1M, including $12.7M in additional stock-based compensation related to the 2026 Parasa Warrant Obligation and $9.1M for undisclosed programs.
- Liquidity: The company had $456.2M in cash and cash equivalents at September 30, 2026, which it expects will fund operating expenses and capital expenditures into 2029.
Original SEC Filing: Korsana Biosciences, Inc. [ KRSA ] - 10-Q - Nov. 05, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.